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T-cells play a critical role in tumor immunity. Indeed, the presence of tumor-infiltrating 
lymphocytes is a predictor of favorable patient prognosis for many indications and is 
a requirement for responsiveness to immune checkpoint blockade therapy targeting 
programmed cell death 1. For tumors lacking immune infiltrate, or for which antigen pro-
cessing and/or presentation has been downregulated, a promising immunotherapeutic 
approach is chimeric antigen receptor (CAR) T-cell therapy. CARs are hybrid receptors 
that link the tumor antigen specificity and affinity of an antibody-derived single-chain 
variable fragment with signaling endodomains associated with T-cell activation. CAR 
therapy targeting CD19 has yielded extraordinary clinical responses against some 
hematological tumors. Solid tumors, however, remain an important challenge to CAR 
T-cells due to issues of homing, tumor vasculature and stromal barriers, and a range 
of obstacles in the tumor bed. Protumoral immune infiltrate including T regulatory cells 
and myeloid-derived suppressor cells have been well characterized for their ability to 
upregulate inhibitory receptors and molecules that hinder effector T-cells. A critical role 
for metabolic barriers in the tumor microenvironment (TME) is emerging. High glucose 
consumption and competition for key amino acids by tumor cells can leave T-cells with 
insufficient energy and biosynthetic precursors to support activities such as cytokine 
secretion and lead to a phenotypic state of anergy or exhaustion. CAR T-cell expansion 
protocols that promote a less differentiated phenotype, combined with optimal receptor 
design and coengineering strategies, along with immunomodulatory therapies that also 
promote endogenous immunity, offer great promise in surmounting immunometabolic 
barriers in the TME and curing solid tumors.
Keywords: immunotherapy, chimeric antigen receptor, T-cells, gene-engineering, immunometabolism, solid 
tumors, tumor microenvironment
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NATURAL TUMOR iMMUNiTY AND 
ReSPONSe TO iMMUNOTHeRAPY
immune Checkpoint Blockade
T  lymphocytes play a critical role in tumor immunity through 
the recognition of tumor-associated antigens processed and 
presented as peptides at the cell surface by major histocompat-
ibility complex (MHC) molecules (1). For various tumor types, 
the presence of tumor-infiltrating T lymphocytes (TILs) predicts 
longer disease-free survival and overall patient survival (2–6). 
Cancers employ numerous mechanisms of immune evasion 
(7) that dampen T-cell activity, which in some patients can be 
successfully reversed by monoclonal antibodies (mAbs) targeting 
immune checkpoints, such as cytotoxic T lymphocyte-associated 
protein 4 (CTLA-4), and the programmed cell death 1 (PD-1)/
PD ligand 1 (PD-L1) axis. These immunomodulatory mAbs have 
enabled regression of a range of malignancies including mela-
noma (8, 9), lung (10), bladder (11), Hodgkin’s lymphoma (12), 
renal-cell carcinoma (13), ovarian (14), as well as gastrointestinal 
and endometrial cancers with DNA mismatch-repair defects (15), 
thus providing proof that the majority of solid tumor types can be 
spontaneously recognized by the host’s T-cells. PD-1 inhibition 
alone is active in about 30% of cancer patients, but in combination 
with CTLA-4 the fraction of responding metastatic melanoma 
patients increases to 57% (16). Notably, clinical responses to 
immunotherapy are usually associated with durability (17).
A number of studies have attempted to elucidate mechanisms 
underlying resistance to checkpoint blockade. The presence of 
CD8+ T-cells within the tumor or its invasive margin is a key 
requirement for responses to PD-1 inhibition (18). Many studies 
indicate that the neoantigen load may also be an influencing factor 
(19–22). However, as the case of Merkel-cell carcinoma (MCC) 
has shown, the quality of tumor epitopes and the corresponding 
TILs, and not only the mutation rate, can confer sensitivity to 
checkpoint blockade; MCC that is virally induced and having a 
low mutation rate responds similar to checkpoint blockade as 
MCC caused by ultraviolet radiation (23, 24). The presence of 
CD8+ TILs has been linked to the expression of a type I interferon 
(IFN) signature in tumors (25, 26) and the recruitment of a subset 
of CD103+/CD8α+ DCs driven by the transcription factor Batf3 
(27, 28). WNT/β-catenin signaling upregulation may be one of 
the tumor cell-intrinsic pathways driving a non-T-cell inflamed 
phenotype, at least in metastatic melanoma (29) for which a 
genetically engineered mouse model revealed reduced expres-
sion of the chemokine CCL4, impaired recruitment of Batf3+ 
DCs and T-cells, and resistance to checkpoint blockade (29). 
Interestingly, commensal bacteria in the gut can also shape innate 
immunity and responses to immune checkpoint therapy (30–32). 
Finally, metabolic circuitries play an important role in regulating 
immune function in tumors. It has recently been demonstrated 
that CTLA-4, PD-1, and PD-L1 blockade can restore glucose 
levels in the tumor microenvironment (TME), thereby improving 
T-cell fitness. Anti-PD-L1 mAb was specifically shown to block 
the mechanistic target of rapamycin [mTOR, a central regulator 
of metabolism and physiology (33)] and decrease the expression 
of glycolytic enzymes in tumor cells (34). Further, for PD-L1+ 
renal-cell carcinoma patients, non-responsiveness to PD-1 block-
ade has been associated with metabolic gene upregulation as well 
as of solute transport functions such as UGT1A family members, 
whereas responders present an immune response profile includ-
ing upregulation of CCL3, a chemokine involved in leukocyte 
migration (35).
TiL and Chimeric Antigen Receptor (CAR) 
T-Cell Therapy
Another powerful form of immunotherapy is adoptive T-cell 
therapy (ACT), which entails the ex vivo expansion of tumor-
specific T-cells and their infusion into a patient. For TIL 
therapy, in which T  lymphocytes are enriched from tumor 
biopsies, patients are typically lymphodepleted and receive 
high-dose interleukin-2 (IL-2) (36–38). TIL therapy has proven 
successful in advanced metastatic melanoma, mediating objec-
tive responses in about 50% of patients, and durable complete 
responses in up to 20% of patients receiving a single TIL infusion 
(36). It is now evident that in the case of metastatic melanoma 
an important target of TILs are mutated gene products (39). 
TIL therapy has also been anecdotally successful in common 
carcinomas (40), suggesting that this approach could be applied 
to other solid tumor indications. For various reasons, however, 
ranging from tumor vasculature barriers to a lack of type I IFN 
signaling, not all tumors are infiltrated by T-cells at baseline 
(27, 41–43).
In the absence of endogenous T-cell infiltrate due to aber-
rant antigen processing and presentation, for example, which 
precludes the use of TIL therapy and immune checkpoint 
blockade, a promising solution for treating cold tumors is 
the transfer of mAb-modified T-cells, so-called CAR T-cells 
(39). In recent years, CD19-targeted CAR T-cell therapy has 
yielded spectacular clinical responses against hematologic 
liquid tumors (44), including up to 90% complete response 
in relapsed or treatment-refractory acute lymphoblastic leu-
kemia (ALL) patients (45). In the solid TME, however, T-cells 
face a battery of physical and immunometabolic barriers 
(46, 47), to which CAR T-cells, like endogenous T-cells, are 
vulnerable (48, 49). CAR T-cells may thus similarly require 
combinatorial regimens of immunomodulation such as 
kinase inhibitors (50), chemotherapy (51), radiotherapy (RT) 
(52), or checkpoint blockade (53), to unleash their full thera-
peutic potential (54–56). CAR T-cells can also be armored 
through additional gene modification (57). For example, 
they have been coengineered to express stimulatory ligands, 
such as CD40 ligand (CD40L) (58), or to secrete stimula-
tory cytokines, such as IL-12 (57), for improved antitumor 
responses. With an emerging awareness of the role played by 
metabolism in both cancer progression and T-cell activity 
in the TME (59), it is apparent that further development of 
CAR T-cell therapy for maximizing functionality in harsh, 
nutrient-depleted conditions is critical. Here, we review 
the design and function of CAR T-cells, immunometabolic 
barriers in the solid TME, and different ex vivo expansion, 
coengineering and combinatorial therapy approaches for 
overcoming them.
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CAR T-CeLL eNGiNeeRiNG
Basic CAR Design
Chimeric antigen receptors, first conceived in the late 1980s 
(60), are hybrid receptors comprising (i) an extracellular tumor-
binding moiety, typically an Ab-derived single-chain variable 
fragment (scFv), (ii) a hinge/spacer, (iii) a transmembrane (TM) 
region, and (iv) various combinations of intracellular signaling 
domains associated with T-cell activation (61). First-generation 
CARs include the endodomain of CD3ζ only (for signal 1 of 
T-cell activation), while second- and third-generation CARs 
also have one or more costimulatory endodomains (for signal 
2), respectively (Figure  1) (62). Finally, armored CAR T-cells 
are further gene modified to express or block molecules and/
or receptors to enhance immune activity. Patient responses to 
first-generation CAR T-cells were disappointing, probably due to 
poor expansion and persistence (63–65) as a result of an anergic 
phenotype (66–68), and most ongoing trials involve second-
generation CARs incorporating either CD28 or 4-1BB (CD137) 
(39, 69). CARs can be transiently expressed in primary T-cells 
by RNA electroporation, typically for about 1 week with current 
technology, or they can be stably incorporated into the genome 
by lentiviral or gamma-retroviral transduction (70), as well as by 
transposon/transposase-mediated integration using the sleeping 
beauty system (71). RNA electroporation along with dosing 
escalation is often used in the testing of new CARs in the clinic. 
To minimize toxicity, molecules secreted by armored CAR T-cells 
can be placed under an inducible promoter (72). To date, there 
have been no safety issues related to viral or transposon-mediated 
genomic integration of CARs (38, 73).
Unlike T-cell receptors (TCRs) that are MHC restricted, CARs 
can potentially bind any cell surface-expressed antigen and can 
thus be more universally used to treat patients. CARs have been 
developed against not only proteins, including the pMHC com-
plex (74), but also against carbohydrates and glycolipids, as well 
as targets upregulated in the tumor stroma (75) and the tumor 
vasculature (42). Notably, not all scFvs are suitable for CAR 
development. A recent study demonstrated antigen-independent 
clustering of an anti-GD2 CAR, caused by the framework region 
sequences, thereby exhausting the cells and limiting antitumor 
responses. Interestingly, it was further shown that 4-1BB was 
superior to CD28 in alleviating exhaustion from this tonic 
signaling (76). In addition, caution should be taken in the use of 
scFvs of murine origin, as human-anti-mouse Ab responses can 
deplete the transferred CAR T-cells, and even result in patient 
death by anaphylactic shock following multiple infusions (77, 
78). Interestingly, similar to TCRs, increasing receptor-binding 
strength can augment T-cell function, but there is an affinity 
threshold beyond which there is no further gain in activity, and 
target density impacts CAR T-cell activation (79–81). Along with 
scFv, other tumor-binding moieties including an anti-integrin 
peptide α5β6 (82), heregulin (83), interleukin 13-zetakine (84), 
NKG2D (85), vasculature endothelial growth factor (VEGF) 
(86), and TCRs (87) have been incorporated into functional 
CARs. Finally, universal CARs, including an avidin ectodomain 
(88) and an anti-FITC scFv (89) for recognizing targets bound 
by biotinylated and FITC-labeled mAbs, respectively, have been 
developed.
CAR T-Cell Safety and Next-Generation 
Receptor Design
Chimeric antigen receptor T-cells are a potent living drug and a 
primary consideration in their development is the choice of target 
antigen. Ideally, it is highly expressed on the tumor and not at 
all on normal cells. Currently, there are about 30 solid tumor 
antigens being evaluated for CAR therapy including mesothelin, 
carcinoembryonic antigen (CEA), the diganglioside GD2, inter-
leukin 13 receptor alpha (IL13Ra), human epidermal growth 
factor 2 (HER-2), fibroblast-activating protein (FAP), and L1 cell 
adhesion molecule (L1CAM) (90, 91). Unfortunately, there have 
been instances of severe on-target/off-site toxicity (92) such as 
a HER-2 CAR that may have caused patient death via reactivity 
with low levels of cognate antigen expressed on lung epithelium 
(93). One approach to circumvent this is to use a lower affinity 
scFv such that the CAR T-cells are only activated in the pres-
ence of high cell-surface expression of antigen (i.e., on the tumor 
cells only) (94–96). Or one can target an antigen that is tumor 
restricted, such as epidermal growth factor receptor variant III 
(EGFRvIII) (97), but there are few such examples.
In recent years various novel, next-generation engineering 
strategies have been devised to improve CAR T-cell safety. For 
example, the signaling can be split by coexpressing two CARs, 
one incorporating CD3ζ and the other the costimulatory 
endodomain, such that the T-cell will only be fully activated 
when both receptors are engaged (98, 99). Bispecific tandem 
CARs (TanCARs; the extracellular domain of one receptor can 
engage two distinct antigens) (100) have also been developed that 
synergistically enhance T-cell activity levels when coengaged. 
More recently, novel synthetic Notch-based receptors have 
been designed that enable combinatorial activation of T-cells— 
binding by the Notch-based CAR upregulates expression of the 
second CAR (101, 102). In addition, innovative ON-Switch/
Remote Control CARs have been developed that restrict T-cell 
activation to tumor cell antigen encounter in the presence of a 
remotely provided heterodimerizing small molecule that links 
the antigen-binding receptor with intracellular components that 
initiate signaling (103). Finally, it is also possible to gene-modify 
CAR T-cells with various suicide genes or safety switches such as 
inducible caspase 9 to cause rapid T-cell destruction in the case 
of an adverse reaction in a treated patient (104, 105). In the event 
of CAR T-cell toxicity, such as cytokine release syndrome (CRS), 
early and aggressive supportive patient care is critical. The current 
mainstay treatment for CRS is IL-6 receptor blockade with the 
monoclonal Ab tocilizumab, but in the case of neurologic toxici-
ties corticosteroids are employed (106).
CAR T-Cell Activity As a Function of 
Receptor Design
The distance between a T-cell and its target antigen-presenting 
cell (APC) of approximately 15 nm is dictated by the TCR–pMHC 
interaction and is critical for the exclusion of large phosphatases 
FiGURe 1 | Properties of first-, second-, and third-generation chimeric antigen receptor (CAR) T-cells. CARs comprise an extracellular tumor-binding 
moiety, typically a single-chain variable fragment (scFv), followed by a hinge/spacer of varying length and flexibility, a transmembrane (TM) region, and various 
combinations of endodomains associated with T-cell signaling. While first-generation CARs include the endodomain of CD3ζ, second- and third-generation CARs 
also have one or more costimulatory endodomain, respectively. The most commonly used costimulatory endodomains are from CD28 and 4-1BB. CAR T-cell 
functionality can vary based on design (scFv affinity, hinge/spacer length, TM domain, etc.) and generation. In general, the 4-1BB endodomain confers the highest 
level of in vivo persistence and resistance to exhaustion. Metabolically, second-generation CD28-based CAR T-cells exhibit enhanced aerobic glycolysis as 
compared to 4-1BB-based ones which demonstrate enhanced respiratory capacity, fatty acid oxidation, and mitochondrial biogenesis. Stimulated CD28-based 
CAR T-cells acquire an effector memory-like phenotype, whereas 4-1BB-based ones take on a central memory-like phenotype.
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such as CD45 and CD148 to the periphery of the immune synapse 
(107), thereby enabling TCR clustering and triggering (1). The 
precise mechanism by which CARs activate T-cells has not been 
fully elucidated, but the hinge/spacer, which governs the spatial 
distance between a CAR T-cell and its target, can significantly 
impact function (108, 109). Various hinge/spacers have been 
incorporated into CARs including regions from CD8α and CD4, 
as well as CH2–CH3 from the Fc domains of IgG1 and IgG4. In 
the case of CH2 spacers derived from IgG4, sequence modifica-
tion is required to prevent Fc receptor binding by myeloid cells 
that can cause activation-induced T-cell death (AICD) (110, 111). 
Most CARs comprise a TM domain from a type I membrane 
protein such as CD4, CD8, CD3ζ, or CD28. Interestingly, it was 
demonstrated that CARs comprising a CD3ζ TM domain engage 
endogenous TCR–CD3 complexes for optimal activity (112). 
CARs can function, however, in the absence of endogenous TCR 
(113), and important efforts are being undertaken to develop 
universal allogeneic T-cell donors for immunotherapy (114).
In general, distal membrane epitopes require a shorter 
hinge/spacer, whereas an epitope that is closer to the tumor cell 
membrane may necessitate a longer and more flexible one to 
facilitate scFv binding and optimal T-cell activity (115). Recently, 
a Strep-tag II has been used to modify spacer length and at the 
same time provide a means of identifying and rapidly purifying 
CAR-engineered T-cells, during both the manufacturing process 
and patient monitoring (116). A notable study comparing three 
L1CAM CARs varying only in hinge/spacer length (short, 
medium, and long) revealed that the CAR conferring the highest 
5Irving et al. Immunometabolic Barriers to T-Cell Therapy
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in  vitro function (long; IgG4 hinge–CH2–CH3 spacer) fared 
poorly in vivo, and, conversely, the weakest CAR in vitro (short; 
IgG4 hinge) performed the best in tumor-bearing mice. The 
authors hypothesized that the limited duration of CAR signaling 
required for in vitro assays does not reflect the recursive rounds 
of activation needed to eradicate a tumor in vivo. Thus, they set 
up a coculture stress test for which CAR T-cells were repeatedly 
harvested and transferred to culture dishes seeded with fresh 
tumor cells. Interestingly, after three rounds, the CAR T-cells 
bearing the long linker (i.e., conferring the best activity in round 
1) underwent the highest level of AICD as a result of upregulated 
FasL–Fas interactions (110). This work highlights a disaccord 
between T-cell responses observed in standard in  vitro testing 
versus in vivo challenges. Establishing in vitro T-cell parameters 
such as receptor affinity/kinetics and two-dimensional interac-
tions (117), functionality upon stress testing (110), gene expres-
sion profiles upon activation, etc., that correlate to maximum 
antitumor responses in vivo is an important area of research for 
the efficient screening of new leads for preclinical and clinical 
testing.
Optimal T-Cell Subsets for CAR Activity
Another important factor governing CAR T-cell activity in vivo 
is the subset of input T-cells used. Based on their differentiation 
and level of maturity, T-cells are presently classified into naïve 
(TN), and four main activated subtypes: stem cell memory (TSCM), 
central memory (TCM), effector memory (TEM), and terminally 
differentiated effector cells (TEFF) (118). For both mouse and 
humans, it has been demonstrated that the less differentiated 
subsets (TSCM and TCM) display better expansion, persistence, 
and antitumor activity in  vivo (119–122). The phenotypic and 
functional properties of human CD8+ TN versus the different 
memory subsets are illustrated in Figure 2. Retrospective studies 
from ACT trials have correlated objective clinical responses in 
patients with the transfer of less differentiated T-cells (123, 124). 
A recent analysis of CD19 CAR-treated patients revealed a cor-
relation between in vivo expansion and the level of infused TSCM 
phenotype (125). There are also studies demonstrating better 
antitumor responses when both CD4+ and CD8+ CAR T-cells are 
transferred (126), and it has proven beneficial to gene-engineer 
virus-specific memory T-cells that can persist long term, pre-
sumably via TCR-mediated survival signals and the quality of 
the original TCR-mediated priming of the cell (127). Although 
T-cell metabolism has long been an active field of study due 
to the remarkable cellular rewiring required to accommodate 
changes in energetic requirements when naïve, quiescent T-cells 
encounter and respond to cognate pMHC, it is only recently that 
it has come to the forefront of cancer research.
iNTeRPLAY BeTweeN THe MeTABOLiC 
ACTiviTY OF T-CeLLS AND FUNCTiON
Metabolic Activity of Naïve T-Cells
All T-cells use glucose as their primary source of fuel for the gen-
eration of adenosine triphosphate (ATP), but there are important 
differences in the metabolic requirements and pathways used by 
naïve, activated, and memory T-cells, which correspond to their 
specific functional state (128). TN cells are quiescent and have lim-
ited biosynthetic needs because their major role is to circulate the 
host with the aim of being primed by an APC. Quiescent T-cells, 
comprising both naïve and memory T-cells, rely on catabolic 
metabolism, whereby nutrients including glucose, fatty acids, and 
amino acids are broken down for fuel (128). Indeed, quiescent 
T-cells mainly undertake oxidative phosphorylation (OXPHOS), 
a process that takes place in the mitochondria involving the 
oxidation of substrates in the tricarboxylic acid (TCA) cycle to 
generate ATP (129) (summarized in Figure 3A). The TCA cycle 
itself is a series of chemical reactions that use metabolic substrates 
to produce reducing agents such as the coenzyme reduced nico-
tinamide adenine dinucleotide (NADH), which donate electrons 
to the electron transport chain. Up to 36 molecules of ATP can be 
generated by OXPHOS per glucose molecule.
Metabolic Activity of effector T-Cells
Upon productive TCR–pMHC engagement and costimulation, 
naïve T-cells become activated and undergo extensive metabolic 
rewiring causing them to enlarge in size, and enabling extensive 
proliferation and the acquisition of effector functions such as 
cytokine secretion (130). Activated T-cells switch to anabolic 
metabolism meaning that nutrients are used to construct molecu-
lar building blocks. This transition is associated with mTOR 
induction, and the expression of the transcription factors Myc 
and hypoxia-inducible factor-1α (HIF-1α) (131, 132). Although 
activated T-cells increase mitochondrial OXPHOS and reactive 
oxygen species production, they also upregulate and rely heavily 
upon aerobic glycolysis (133) to meet their metabolic needs (134, 
135) (Figure 3B). Upon T-cell activation, there is an increase in 
the expression of the glucose receptor Glut1, as well as glycolytic 
enzymes to enable increased import of glucose that is converted 
to glucose-6-phosphate and eventually pyruvate that is finally 
secreted in the form of lactate. It has recently been demonstrated 
that T-cells activated under hypoxic conditions upregulate sig-
nificantly higher levels of Glut1 than under atmospheric oxygen 
(136), but the reactivation of CD8+ T-cells under hypoxia has 
also been shown to switch them toward a poorly proliferative and 
IL-10 secreting phenotype (137). This phenomenon of aerobically 
fermenting glucose to lactate, despite sufficient oxygen to support 
OXPHOS, a process also utilized by tumor cells, which them-
selves are heavy consumers of glucose, is known as the Warburg 
effect (138, 139).
Aerobic glycolysis is energetically less efficient than OXPHOS, 
generating only two molecules of ATP per glucose molecule, but 
the process is rapid and in addition supplies a critical source 
of metabolic intermediates needed for the synthesis of nucleic 
acids, proteins, carbohydrates, and lipids, and it provides a 
means of maintaining the NAD+-NADH redox balance (138). 
Glycolytic metabolites also help to sustain effector functions 
through transcriptional and translation regulation (59). For 
example, glyceraldehyde-3-phosphate promotes IFNγ produc-
tion by relieving its restraint by glyceraldehyde-3-phosphate 
dehydrogenase (140). In addition, Ho et  al. demonstrated that 
phosphophenolpyruvate (141) accumulation can help sustain the 
Ca2+-NFAT pathway, which controls the production of effector 
FiGURe 2 | Differentiation of naïve T-cells to memory subsets upon priming in secondary lymphoid organs. The differentiation state of T-cells depends 
upon the strength and duration of priming naïve T-cells receive from antigen-presenting cells in the secondary lymphoid organs. In general, the more differentiated 
the T-cell, as a result of more robust priming, the lower its proliferative and self-renewal capacity, and the poorer its antitumor control in the context of adoptive T-cell 
therapy. The different memory T-cell subsets can be distinguished based on their expression of various cell-surface markers including the tyrosine phosphatase 
CD45 (full length = CD45RA, truncated form = CD45RO), the lymph node homing receptors, chemokine receptor 7, and CD62 ligand, as well as CD95 (Fas 
receptor), interleukin-2 receptor β-chain, and the costimulatory receptor CD28.
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molecules, by inhibiting ER Ca2+ reuptake. It has been shown that 
activated T-cells can switch between OXPHOS and aerobic glyco-
lysis depending on their environment, but glycolysis is required 
for full effector function—if activated T-cells revert to OXPHOS 
it will be at the expense of IL-2 and IFNγ production (140). In 
addition to glucose, activated T-cells rely upon an extracellular 
supply of glutamine to replenish intermediates for the TCA 
cycle through the process of glutaminolysis, and this can also 
contribute to the citrate pool used for lipid synthesis by reductive 
carboxylation (142, 143). Finally, activated T-cells decrease fatty 
acid oxidation (FAO), decrease pyruvate flux into the TCA cycle, 
and increase glucose flux into the pentose phosphate pathway to 
produce nucleotides for DNA synthesis (Figure 3B).
Metabolic Activity of Memory T-Cells
By contrast, memory T-cells transition from aerobic glycolysis to 
OXPHOS, fueled in part by the catabolism of intracellular fatty 
acids in the mitochondria (144–146). Furthermore, memory 
T-cells have increased mitochondrial mass and activity (147, 148) 
and upregulate mitochondrial biogenesis to build substantial spare 
respiratory capacity (SRC), thereby enabling both survival and 
rapid recall to antigen challenge (130) (Figure 3C). Interestingly, 
memory T-cells activated in vitro increase aerobic glycolysis, and 
consequently IFNγ production, more rapidly than their naive 
counterparts. How this relates to their capacity to compete for 
glucose in the TME remains to be established (149). Moreover, 
memory T-cells can potentially better adapt to a nutrient crisis 
because they have healthier mitochondria (147). AMP-activated 
protein kinase (AMPK) is another important metabolic regulator 
in T-cells that senses a high AMP to ATP ratio and can promote 
catabolic pathways and conservation of energy during metabolic 
stress. AMPK is important for memory T-cell development (150); 
treating activated CD8+ T-cells with either rapamycin (inhibits 
mTOR) or metformin (activates AMPK) to augment catabolic 
pathways enhances CD8+ memory formation (151, 152).
immunometabolism and T-Cell Therapy
It has been observed that several genes involved in metabolism 
are downregulated in exhausted T-cells (153). Moreover, blocking 
leucine or glucose metabolism during T-cell activation leads to an 
anergic phenotype (154). Mechanistically, leucine can stimulate 
mTOR via leucyl-tRNA synthetase and hence low leucine levels 
FiGURe 3 | General metabolic profiles of naïve, activated, and memory T-cells. (A) Naïve T-cells are quiescent and perform catabolic metabolism to 
accommodate basic energy requirements. (B) Activated effector T-cells, whereas switch to anabolic metabolism to meet increasing energy demands as well as for 
biosynthesis to support functionality including proliferation, growth, and cytokine secretion. (C) Memory cells, like naïve cells, are quiescent and perform metabolic 
catabolism. While naïve and memory T-cells mostly rely on oxidative phosphorylation (shown in orange), activated ones are metabolically rewired to upregulate 
aerobic glycolysis (shown in red). Activated T-cells also require glutaminolysis (in green) and the pentose phosphate pathway (in navy blue) to support their activities. 
Memory T-cells rely on fatty acid oxidation (in purple) and they have increased mitochondrial mass and maintain substantial spare respiratory capacity to enable 
survival and rapid recall to antigen challenge. A brief summary of the major metabolic mechanisms is described in the inlet.
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may impair mTOR activation (155, 156). It has also been dem-
onstrated that both PD-1 and CTLA-4 ligation inhibits glycolysis 
in activated T-cells but through distinct mechanisms; CTLA-4 
inhibits Akt via the serine–threonine phosphatase PP2A, while 
PD-1 inhibits Akt phosphorylation by blocking CD28-mediated 
activation of PI3K (157). PD-1 signaling also blocks amino acid 
metabolism but promotes fatty acid β-oxidation (158). With an 
increased appreciation for the high competition for nutrients 
8Irving et al. Immunometabolic Barriers to T-Cell Therapy
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including glucose in the TME which can promote tumor progres-
sion, as well as the dynamic interplay between T-cell phenotype, 
metabolism, and immune checkpoint, it is clear that an important 
consideration in the development of CAR T-cells is how their 
culture prior to transfer, as well as their design, affects their 
metabolic profile.
Traditionally, T-cells for ACT are cultured with high doses of 
IL-2, followed by a rapid expansion protocol comprising agonistic 
anti-CD3 Ab and allogeneic feeder cells (159). However, it is now 
known that TCR signaling coupled with high-dose IL-2 drives 
TEFF differentiation (160) which is not an ideal phenotype for ACT. 
Alternative common gamma chain (γc) signaling cytokines have 
also been assessed for T-cell culture. Naïve mouse T-cells cultured 
in the presence of IL-15 (145) or IL-21 (161), for example, acquire 
phenotypic, functional, and metabolic properties of naturally 
occurring TCM cells. Moreover, IL-15 cultured murine T-cells 
confer superior in vivo antitumor activity than ones cultured in 
IL-2 (162). Similarly, human T-cells cultured with artificial APCs 
and IL-15 exhibit a TCM phenotype, demonstrate clonotypic 
persistence, and can mediate objective clinical responses upon 
transfer (163, 164). Human T-cells cultured in IL-21 also main-
tain a minimally differentiated profile (161, 165). Interestingly, it 
has been demonstrated that IL-15 regulates SRC and oxidative 
metabolism by mitochondrial biogenesis as well as the expression 
of carnitine palmitoyl transferase, a metabolic enzyme involved 
in the rate-limiting step in FAO (145). IL-7 also enhances T-cell 
survival in a metabolically driven manner by Glut1 trafficking via 
STAT5 and Akt (166), as well as by inducing glycerol transport 
(via AQP9) and triglyceride synthesis (167). Finally, metaboli-
cally robust T-cells isolated with the lipophilic cationic dye tetra-
methylrhodamine methyl ester (TMRM; staining can be used 
to distinguish mitochondrial membrane potential) conferred 
enhanced persistence and tumor eradication upon ACT (168).
A T-cell’s commitment between a memory versus effector 
phenotype is governed by its metabolic state (145, 152, 169), 
which in turn is controlled by stimuli from TCR, costimulatory 
and cytokine receptors that converge at common development, 
and differentiation signal transduction pathways including PI3K/
Akt/mTOR and Wnt/β-catenin (130). Thus, small molecule 
modulators of these pathways have been assessed for the in vitro 
culture of T-cells for ACT. Promotion of the canonical Wnt/β-
catenin pathway with the GSK3β inhibitor TWS119, for example, 
favors the formation of TCM and TSCM cells with improved in vivo 
antitumor responses as compared to untreated cells (170). 
Similarly, Akt inhibition during ex vivo priming and expansion 
of T-cells favors TSCM-like cells having higher rates of OXPHOS 
and FAO and enabling enhanced in  vivo tumor control (171). 
Another consideration in T-cell culture for ACT is glucose con-
centration in the media. Although media often comprise about 
5.5 mM glucose (similar to that of blood), many used for ACT 
are in the range of 10–25 mM—this may program high depend-
ency on glucose and thereby further impair T-cell responses 
in the nutrient-deprived TME (169, 172). Interestingly, it has 
been shown that the activation of CD8+ T-cells in the presence 
of 2-deoxyglucose, an inhibitor of glycolysis, enhances memory 
generation and antitumor responses (169). Several amino acids 
have been implicated in immunomodulation including cysteine, 
glutamine, phenylalanine, tryptophan, and arginine (173). It has 
been observed that low arginine, for example, induces the loss 
of CD3ζ and inhibits proliferation and cytokine production by 
T-cells, but that this state can be reversed by exposure to excess 
arginine (174). Recently, it has been further demonstrated that 
the culture of murine T-cells with elevated l-arginine promotes 
the generation of TCM-like cells, shifts the metabolic profile from 
glycolysis to OXPHOS, and endows the T-cells with enhanced 
antitumor activity in vivo (175).
CAR endodomains and Metabolism
As previously mentioned, in recent years, there have been 
important clinical responses to CD19 CAR T-cell therapy against 
hematological tumors including ALL, chronic lymphocytic leu-
kemia (CLL), and diffuse large B cell lymphoma, using second-
generation receptors comprising either CD28 or 4-1BB [reviewed 
in Ref. (44)]. It is oftentimes difficult to compare the success of 
trials because of differences in the study design, including the scFv 
used, the gene transfer protocols, and interventions undertaken 
post-transfer. Initial clinical response rates against ALL have 
been the same for CD19 CAR trials incorporating either CD28 
or 4-1BB (45, 176, 177). In the case of CLL, however, 4-1BB-based 
CAR T-cells appear superior (178), demonstrating persistence of 
greater than 4 years in some patients versus 30 days in the case of 
CD28 (179). Signaling pathways induced by CD28 versus 4-1BB, 
a member of the tumor-necrosis receptor family, are distinct. 
While CD28 activates the PI3K/Akt pathway that can enhance 
glycolysis (180), 4-1BB has been linked to long-term survival of 
T-cells (181). Recently, the metabolic pathways induced by the 
CD28 versus the 4-1BB costimulatory endodomain of second-
generation CD19 CAR T-cells were described for the first time 
(182). T-cells engineered with a 4-1BB-bearing CAR had an 
increased frequency of TCM phenotype, mitochondrial biogen-
esis, and oxidative metabolism upon activation, and had greater 
survival, as compared to the CD28-based CAR T-cells that had 
enhanced aerobic glycolysis and a predominantly TEM phenotype 
(Figure 1). This work has important implications in the choice 
of CAR costimulatory endodomains for targeting different solid 
TMEs. For example, in the case of a tumor such as BRAF V600E 
melanoma, which has a high glycolytic rate (183), it may be pru-
dent to develop a CAR incorporating 4-1BB. Pretreatment with a 
BRAF inhibitor may also help in restoring glucose levels prior to 
ACT for improved T-cell activity in the TME. Alternatively, it may 
be beneficial to transfer both CD28 and 4-1BB-based CAR T-cells 
for both immediate effector and persistent antitumor activity.
ARMOReD CAR T-CeLLS AND 
COMBiNATiON THeRAPieS TO 
OveRCOMe iMMUNOMeTABOLiC 
OBSTACLeS iN SOLiD TUMORS
immunometabolic Obstacles in Solid 
Tumors
The clinical efficacy of CAR T-cells against solid tumors remains 
to be proven (184). The two most successful trials to date involve 
HER-2 CAR T-cells against sarcoma, for which 4/17 patients 
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showed stable disease (185), and GD2 CAR T-cells to treat 
neuroblastoma, for which 3/11 patients underwent a complete 
response (186). There are various physical and physiological hur-
dles faced by T-cells in the context of solid tumors (46). To begin 
with, T-cells must successfully, (i) home to the tumor bed, often 
in the face of mismatches between T-cell chemokine receptors 
and chemokines present in the TME. Furthermore, T-cells must 
migrate along, (ii) an aberrant vasculature that is not conducive 
to transendothelial migration of T-cells due to downregulation 
of adhesion molecules (ICAM-1) (42) and the upregulation of 
FasL (187), etc., and they can encounter, (iii) additional barriers 
in the stroma, including a dense collagen matrix and suppres-
sive cancer-associated fibroblasts (47). If T-cells are successful 
in penetrating the tumor bed, there they can face a battery of 
obstacles, including (iv) suppressive immune infiltrate compris-
ing T regulatory cells (Tregs), myeloid-derived suppressor cells 
(MDSCs), tumor-associated macrophages, tumor-associated 
neutrophils (188), and immature DCs (189), (v) a range of 
suppressive molecules such as transforming growth factor beta 
(TGFβ) VEGF and adenosine, (vi) suppressive ligands including 
PD-L1/L2, VISTA, and FasL (190), (vii) competition for, and 
downregulation of, costimulatory ligands such as CD80/86, and 
(viii) T-cell-intrinsic regulatory mechanisms including PD-1 and 
CTLA-4 upregulation, and ultimately exhaustion (191) or anergy 
(192). Finally, (ix) the T-cells must function in an environment 
that is acidic, hypoxic (193), nutritionally depleted (194) and 
comprising toxic metabolic by-products such as lactic acid, 
glutamate, and ketone bodies (195) (summarized in Figure 4).
CAR T-Cell Coengineering and 
Combinatorial Therapy for Tumor Homing 
and Migration into the Tumor Bed
The predominant chemokine receptor mediating effector T-cell 
recruitment to tumors is CXCR3 via chemokines CXCL9 and 
CXCL10 (196). Chemokines commonly secreted in TMEs, 
however, rather than attracting cytotoxic T-cells often recruit 
inhibitory immune cells such as Tregs and MDSCs, whose 
presence is associated with poor patient prognosis (197). The 
chemokine CCL22, for example, present in breast and prostate 
cancer, mediates CCR4-dependent Treg trafficking (197, 198), 
while hypoxia-dependent expression of the chemokine ligand 
CCL28 in ovarian cancer recruits Tregs via CCR10 (199), and in 
pancreatic cancer the upregulation of CCL5 induces the migra-
tion of CCR5-expressing Tregs (200). Tregs are potent inhibitors 
of CD8+ T-cells as they compete for IL-2 (201), generate adeno-
sine by CD39/CD73 (202), and via CTLA-4 downregulate CD80/
CD86 on DCs that are needed by T-cells for costimulation (203) 
while upregulating indoleamine 2,3-dioxygenase-1 (IDO-1) in 
DCs (204, 205). MDSCs can be recruited to different TMEs by 
CCL2, CXCL5, CXCL12, and stem cell factor (206). They also 
inhibit tumor immunity by various mechanisms including the 
expression of arginase, TGFβ, cyclooxygenase 2 that controls 
prostaglandin E2 (PGE2) production (207) (a powerful repressor 
of TCR signaling), and IL-10. In addition, MDSCs can sequester 
cysteine and induce Tregs (188). One approach to direct CAR 
T-cells (Figure 5A) toward a tumor that does not express CXCL9 
or CXCL10 is to coengineer them with a borrowed chemokine 
receptor (Figure  5B). For example, CXCR2-engineered T-cells 
(208, 209) demonstrated improved localization and control of 
melanoma tumors expressing CXCL1 and CXCL8, chemokines 
that enable the migration of CXCR2+ monocytes.
In order to tackle the stroma, FAP-directed CAR T-cells have 
been developed, and in murine tumor models have been shown 
to slow tumor growth (49). The observation that in vitro cultured 
T-cells downregulate heparanase, an enzyme that is required for 
the degradation of heparin sulfate proteoglycans, the primary 
component of the extracellular matrix of tumor stroma, led to 
the development of CAR T-cells coengineered to secrete it (210) 
(Figure  5C). Such CAR T-cells may be potent against stroma-
rich solid tumors. Various approaches can be taken to normalize 
the tumor vasculature (42). For example, blocking endothelin 
B receptor (211), and the pharmacologic inhibition of VEGF 
and PGE2 to attenuate FasL expression, enables enhanced CD8+ 
T-cell influx and tumor control (187). In addition, CAR T-cells 
that disrupt the tumor vasculature and mediate tumor regression 
have been developed (212).
CAR T-Cell Coengineering and 
Combinatorial Therapy for Overcoming 
immunometabolic Challenges in the 
Tumor Bed
The solid TME is hostile for effector T-cells. As a result of high 
aerobic glycolysis by tumor cells, as well as the fact that nutrients 
and oxygen must be supplied, and waste removed, by an aber-
rant vasculature, tumors are typically nutrient depleted, hypoxic, 
acidic, and toxic. As previously described, low glucose levels and 
a lack of critical amino acids such as leucine and arginine will 
alter T-cell metabolism and directly impair their function (156, 
213, 214). Gene-engineering approaches to render CAR T-cells 
more competitive in nutrient acquisition, such as by overexpress-
ing transporters (Figure 5G), or to rewire their metabolism, may 
improve their activity in solid tumors. For example, overexpres-
sion of PPAR-gamma coactivator 1-α (PGC1-α), a transcriptional 
coactivator involved in mitochondrial biogenesis, could in part 
reverse metabolic exhaustion (decreased mitochondrial mass 
and function induced by chronic Akt signaling) of T-cells in the 
TME (215) (Figure  5I). Interestingly, modulating cholesterol 
metabolism can enhance antitumor response of CD8+ T-cells; 
both pharmacological inhibition and gene knockdown of the 
cholesterol esterification enzyme ACAT1 increased plasma 
membrane concentration of cholesterol, enabling more efficient 
immune synapse formation, TCR clustering, and enhanced sign-
aling (216). Whether such strategies would also augment CAR 
T-cell activity remains to be determined.
Various other immunometabolic gene-engineering strategies 
have been proposed for increasing the activity of TCR- or CAR-
engineered T-cells in the TME. With respect to the PD-1/PD-L1 
checkpoint blockade axis, at least three different approaches have 
been taken. PD-1 has been knocked down in T-cells (217, 218), 
hybrid receptors comprising the ectodomain of PD-1 and the 
endodomain of CD28 have been expressed to divert PD-L1 bind-
ing toward costimulatory intracellular signaling (219), and CAR 
FiGURe 4 | Barriers in the solid tumor microenvironment (TMe) that can hinder chimeric antigen receptor (CAR) T-cell activity. In order to mediate an 
antitumor response, CAR T-cells must first successfully home to and penetrate the tumor bed. Obstacles to these events include tumor chemokine and T-cell 
chemokine receptor mismatches, and various inhibitory mechanisms in the vasculature such as ICAM-1 downregulation. In the stroma, T-cells can be physically 
blocked by dense extracellular matrix and by inhibitory cancer-associated fibroblasts. The TME itself is also hostile, comprising a range of inhibitory immune cells, 
inhibitory receptors such as PD-L1 on tumor cells and immune infiltrate alike, and soluble molecules such as TGFβ that impair T-cell activity (some examples are 
shown). In addition, the TME is typically acidic, hypoxic, full of toxic metabolites, and nutrient depleted which can inhibit not only T-cell activity but also other immune 
infiltrate such as DCs that lose their ability to mature and provide support to T-cells. Moreover, some of these conditions promote protumoral immune cells.
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T-cells have been engineered to secrete anti-PD-L1 Abs (220), 
all of which have been reported to increase antitumor responses 
(Figures 5D,H,J). Others have knocked-down master regulators 
of T-cell activity such as the E3 ubiquitin ligase Cbl-b (Figure 5J) 
and have shown enhanced antitumor T-cell responses (221, 
222). microRNAs, such as miR155, have also been manipulated 
for enhanced tumor control (223, 224) (Figure 5K), and T-cells 
have been gene engineered to overexpress cytokines including 
IL-12 (225) and IL-15 (226) (Figure 5E) for improved activity. 
The advantage of secreted molecules is that they can support not 
only the T-cell that produces them but also endogenous immune 
cells in the TME. As a final example, coengineering CAR T-cells 
to constitutively express CD40L demonstrated enhanced T-cell 
proliferation and secretion of pro-inflammatory cytokines 
(Figure 5F). The CD40L+ CAR T-cells also increased the immu-
nogenicity of CD40+ tumor cells through the upregulation of 
costimulatory, adhesion, and human leukocyte antigen molecules, 
as well as the Fas death receptor, and they induced the maturation 
and secretion of IL-12 by monocyte-derived DCs (58).
The TME can also reprogram other immune infiltrate to the 
detriment of T-cell activity. For example, the maturation, func-
tion, and phenotype of DCs can be impaired by VEGF (227), IL-6, 
macrophage colony-stimulating factor (228), and TGFβ (229). In 
addition, PD-L1 expression by DCs can be induced by IL-10 and 
VEGF (230). It was also recently demonstrated that HIFα expres-
sion [the main transcriptional factors responding to limited 
oxygen supply (231)] elevates miR-210 in MDSCs, which in turn 
increases both arginase activity and the production of nitric oxide 
(232). Along with hypoxia (233), lactate, a major byproduct of 
aerobic glycolysis in tumor cells, can also directly and indirectly 
inhibit cytotoxic T  lymphocyte activity. Indeed, high lactate in 
the TME can block the export of endogenous lactate produced 
FiGURe 5 | T-cell coengineering strategies to target and attack solid tumors, and overcome immunometabolic barriers. Human T-cells, ideally minimally 
differentiated, can be gene-engineered ex vivo in various ways including transient RNA electroporation and stable genome integration by lentiviral transduction and 
sleeping beauty. (A) To enable tumor specificity, the T-cell can be engineered with a chimeric antigen receptor (CAR) directed against a surface-expressed tumor 
antigen (or a TCR against a target pMHC). (B) To enable tumor homing the T-cell can be coengineered to express a specific chemokine receptor that matches the 
chemokine profile of the tumor being targeted. (C) To better penetrate dense stroma CAR T-cells can be coengineered to secrete heparanase. (D) Instead of 
injecting the patient with checkpoint blockade monoclonal antibodies (mAbs), the T-cells can be gene engineered to secrete anti-PD ligand 1 (PD-L1) mAb. (e) The 
tumor microenvironment (TME) often lacks T-cell promoting cytokines, either because they are not produced, or because they are competitively consumed, such as 
IL-2 by T regulatory cells. Thus, CAR T-cells can be coengineered to forcibly secrete various cytokines that can serve not only to self-sustain the CAR T-cell but also 
to stimulate other adaptive and innate immune cells in the TME. (F) Forced expression of the stimulatory ligand CD40L will help activate antigen-presenting cells as 
well as upregulate adhesion molecules on endothelial cells. (G) The upregulation of nutrient transporters for glucose or amino acids may help to increase T-cell 
competition for limited resources in the TME. (H) Hybrid receptors such as ones comprising the extracellular domain of PD-1 fused to the endodomain of CD28 can 
turn a negative signal (i.e., from PD-L1) into one that costimulates the cell. This may be further improved by designing a higher affinity variant of PD-1. (i) The 
overexpression of intracellular proteins such as the transcription coactivator PGC1-α, can help to reverse metabolic exhaustion. (J) Using various techniques 
including CRISPR/cas9, it is possible to knockout gene expression such as of PD-1 and the master regulator Cbl-b to enhance T-cell activity in the TME. (K) 
microRNAs play an important role in T-cell activity and the overexpression of miR-155, for example, can be used to enhance sensitivity to homeostatic γc cytokines. 
Note that some of these approaches have yet to be demonstrated for engineered CAR T-cells.
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by aerobic glycolysis in T-cells via the gradient-dependent trans-
porter monocarboxylate transporter-1, and thereby disturb T-cell 
metabolism (234). Lactic acid can also promote M2-polarization 
and expression of arginase-1 by HIF-1α stabilization (235). 
Moreover, hypoxia, via HIF-1, can induce glycolysis as well as 
a switch from glucose to glutamine as the major substrate for 
FA synthesis in tumor cells (236), further depleting the TME of 
vital nutrients needed for T-cell function. Thus, pretreatment of 
tumors with inhibitors of either HIF-1 or metabolic enzymes 
could potentially impair the metabolic flexibility of cancer cells 
and inhibitory immune infiltrate, thus rendering tumors more 
sensitive to CAR T-cell transfer—the CAR T-cells will benefit 
from entering a more nutrient replete and less aggressive/sup-
pressive TME. Alternatively, metabolic drugs could be targeted 
to tumors with Abs, or the pharmacologic inhibitors could be 
designed in such a way that they are preferentially taken up by 
tumor cells.
A range of other strategies can be used to pretreat or 
cotreat tumors for enhanced responses to CAR T-cell therapy. 
Localized RT, for example, can reprogram the TME by various 
mechanisms including by inducing immunogenic cell death (52, 
237), supporting T-cell trafficking to the tumor (238), and by 
promoting the polarization of macrophages (239) from a sup-
pressive M2 (240) to M1 phenotype (241). An inhibitor of DNA 
methyltransferase 1 (catalyzes the methylation of genetic loci), 
5-aza-2′-deoxycytidine, has been used to enhance expression of 
the epigenetically silenced chemokines CXCL9 and CXCL10 in 
the TME and thereby promote T-cell infiltration and responses 
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to checkpoint blockade (242). CAR T-cells expressing CXCR3 
could benefit from such treatment. Cyclophosphamide, such as 
RT, can be used not only to direct tumor cell destruction but also 
to deplete Tregs from the TME and thereby enhance responses 
to immunotherapy (51). As a final example, IDO-1 inhibition is 
a powerful approach for promoting tumor immunity. IDO-1, the 
rate-limiting enzyme involved in the conversion of the essential 
amino acid tryptophan to its catabolic product kynurenine (Kyn) 
(204, 243), can be upregulated in DCs, by Tregs as mentioned 
above, as well as by tumor cells and myeloid cells in response to 
IFNγ (244, 245), and has been associated with poor prognosis for 
several types of cancer including ovarian (246), endometrial (247), 
colorectal (248), and lung (249). The depletion of tryptophan 
in the TME activates stress response kinases in T-cells, includ-
ing general control non-depressing 2 (GCN2), which detects 
uncharged tRNAs, and ultimately blocks T-cell proliferation and 
triggers the caspase pathway (250, 251). In addition, Kyn binds 
the arylhydrocarbon receptor, a ligand-activated transcription 
factor that promotes the polarization of naïve T-cells toward a 
Treg phenotype (251). Thus, IDO-1 inhibition promotes trypto-
phan availability for effector T-cells and limits Tregs in the TME.
CONCLUDiNG ReMARKS
Metabolism is an important driver of cancer progression that 
must be addressed in the context of CAR T-cell immunotherapy 
to improve clinical responses against solid tumors. High levels 
of aerobic glycolysis by tumor cells leads to an accumulation of 
metabolic by-products that, along with oxygen deprivation and 
low pH, can drive protumoral activity of various immune cells, 
including Tregs and M2 macrophages, as well as directly inhibit 
effector T-cell function. In addition, competition for critical 
nutrients, such as the amino acids tryptophan, glutamine, and 
arginine, as well as glucose, all contribute to the suppression of 
T-cell activity. Checkpoint pathways are intimately linked with 
the metabolic status of both tumor cells and T-cells; non-respon-
siveness to anti-PD-1 mAb has been linked to the upregulation 
of a metabolic gene-signature in tumors (35), whereas successful 
PD-L1 blockade has been demonstrated to block tumor cell 
glycolysis, thereby enhancing T-cell fitness (34).
Immunometabolic barriers can be targeted therapeutically 
prior to and/or during ACT to enhance responses to CAR T-cell 
therapy and to support endogenous immunity. In addition, 
CAR T-cells can be optimally designed based on the metabolic 
properties of the tumor being targeted and cultured to promote 
a less differentiated, long-lived phenotype that can efficiently 
self-renew and differentiate in  vivo into potent effector cells 
(252, 253). Further, CAR T-cells can be coengineered to enhance 
both their own activity and that of other immune cells in the 
TME. Emerging knowledge on the immunometabolic pathways 
regulating T-cell function in tumors offers new opportunities 
for gene-engineering to drive favorable T-cell energetics and 
optimize their activity. Next-generation CAR T-cell immuno-
therapy based on combinatorial engineering and treatments to 
reprogram T-cell properties and the TME offer unprecedented 
hope for curing solid tumors.
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